69/100
✓ Peer-reviewed
alzhub usefulness score 69 out of 100.
·
JAMA network open
·
2020-07-01
The findings of this cohort study suggest that among older Medicare patients undergoing surgical treatment, a diagnosis of a PND was associated with an increase in health care costs for up to 1 year following the surgical procedure. 5 key findings →
Design: cohort study
Participants: 473
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
69/100
✓ Peer-reviewed
alzhub usefulness score 69 out of 100.
·
JAMA network open
·
2020-01-03
This study found that the prevalence of maternal psychological distress in healthy, well-educated, and employed pregnant women was high, underappreciated, and associated with impaired fetal brain biochemistry and hippocampal growth as well as accelerated cortical folding. 5 key findings →
Design: cohort study
Participants: 193
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
68/100
✓ Peer-reviewed
alzhub usefulness score 68 out of 100.
·
JAMA network open
·
2021-04-01
These findings suggest that benzoate treatment may improve cognitive function in women with later-phase dementia. 5 key findings →
Participants: 97
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
68/100
✓ Peer-reviewed
alzhub usefulness score 68 out of 100.
·
JAMA network open
·
2019-05-03
In this study, lower AD signature region volumes, brain microhemorrhages, higher WMH volumes, and infarcts were risk factors associated with dementia in older community-based residents. 4 key findings →
Design: cohort study
Participants: 1,553
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
68/100
✓ Peer-reviewed
alzhub usefulness score 68 out of 100.
·
JAMA network open
·
2021-07-01
This cohort study found that COVID-19 mortality decreased over time during 2020 and that patient demographic characteristics and comorbidities were associated with higher clinical severity. 5 key findings →
Design: cohort study
Participants: 174
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
67/100
✓ Peer-reviewed
alzhub usefulness score 67 out of 100.
·
JAMA network open
·
2023-04-03
Innovations associated with the bayesian approach can improve the efficiency of drug development and the accuracy of clinical trials, even in the context of substantial data missingness. 3 key findings →
Design: clinical trial
Participants: 854
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
67/100
✓ Peer-reviewed
alzhub usefulness score 67 out of 100.
·
JAMA network open
·
2019-08-02
Thirty-five studies were analyzed with data from 3268 caregivers (pooled mean age [SD of sample means], 63.48 [5.99] years; 76.7% female) were analyzed. 3 key findings →
Design: meta-analysis
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
67/100
✓ Peer-reviewed
alzhub usefulness score 67 out of 100.
·
JAMA network open
·
2019-04-05
Dementia risk may be attenuated by physical activity (PA); however, the specific activity levels optimal for dementia prevention are unclear. 4 key findings →
Design: cohort study
Participants: 1,604
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
67/100
✓ Peer-reviewed
alzhub usefulness score 67 out of 100.
·
JAMA network open
·
2022-09-01
Individual conditions have been identified as risk factors for dementia; however, it is important to consider the role of multimorbidity, as conditions often co-occur. 4 key findings →
Design: cohort study
Participants: 960
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
67/100
✓ Peer-reviewed
alzhub usefulness score 67 out of 100.
·
JAMA Network Open
·
2024-12-12
The study consisted of 20 400 patients (9264 female [45.4%]; 1576 Black [7.7%], 3944 Latinx [19.3%], and 10 480 White [51.4%]), including 5100 patients with mTBI (median [IQR] age, 36.0 [25.0-51.0] years), 5100 patients with msTBI (median [IQR age, 35.0 [25.0-52.0] years), and 10 200 matched patients in the control group (median [IQR] age, 36.0 [25.0-51.0] years). 5 key findings →
Design: cohort study
Participants: 400
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
67/100
✓ Peer-reviewed
alzhub usefulness score 67 out of 100.
·
JAMA Network Open
·
2026-01-28
Among 11 601 participants (mean [SD] age, 59.18 [9.41] years; 5569 male [48.0%]), 9145 (78.8%) were exposed to at least 1 ACE indicator, 4241 (36.6%) to at least 1 AAE indicator, and 3531 (30.4%) to both ACE and AAE markers. 5 key findings →
Design: cohort study
Participants: 601
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
67/100
✓ Peer-reviewed
alzhub usefulness score 67 out of 100.
·
JAMA network open
·
2019-12-02
Data from 362 study participants were analyzed (mean [SD] age, 65.6 [7.9] years), of whom 152 (42.0%) were African American, 230 (63.5%) were women, and 189 (52.2%) had MCI. 4 key findings →
Design: case-control study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
67/100
✓ Peer-reviewed
alzhub usefulness score 67 out of 100.
·
JAMA network open
·
2021-07-01
Racial/ethnic groups differed in sources of recruitment, reasons for screen failure, and overall probability of eligibility in a preclinical AD trial. 5 key findings →
Design: cross-sectional
Participants: 5,945
Evidence: low
Full summary, score breakdown and related studies →
Original source
66/100
✓ Peer-reviewed
alzhub usefulness score 66 out of 100.
·
JAMA Network Open
·
2024-10-01
These findings indicate that AWV recipients had a timelier first MCI diagnosis than those who did not receive an AWV, but first ADRD diagnosis differed little. 5 key findings →
Design: cohort
Participants: 549,516
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
66/100
✓ Peer-reviewed
alzhub usefulness score 66 out of 100.
·
JAMA Network Open
·
2024-09-03
In this cohort study, high adherence to a flavonoid-rich diet score was associated with a lower risk of dementia, with reductions more pronounced in individuals with a high genetic risk, hypertension, and depressive symptoms. 5 key findings →
Design: cohort
Participants: 121,986
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
66/100
✓ Peer-reviewed
alzhub usefulness score 66 out of 100.
·
JAMA network open
·
2025-02-03
For the intention-to-treat analysis, 60 patients between ages 51 and 82 years (mean [SD], 70.65 [8.16] years; 30 females; 30 males) were included. 5 key findings →
Participants: 30
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
66/100
✓ Peer-reviewed
alzhub usefulness score 66 out of 100.
·
JAMA network open
·
2023-11-01
Physical exercise and cognitive and social enrichment activities can enhance cognitive function in patients with chronic stroke, but their cost-effectiveness compared with a balance and tone program is uncertain. 5 key findings →
Participants: 120
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
66/100
✓ Peer-reviewed
alzhub usefulness score 66 out of 100.
·
JAMA network open
·
2019-11-01
A cohort of 4 522 160 US veterans (4 243 462 [93.8%] male; median [interquartile range] age, 64.1 [55.7-75.5] years; 3 702 942 [82.0%] white, 667 550 [14.8%] black, and 145 593 [3.2%] other race) was followed up for a median (interquartile range) of 10.0 (6.8-10.2) years. 5 key findings →
Design: cohort study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
66/100
✓ Peer-reviewed
alzhub usefulness score 66 out of 100.
·
JAMA network open
·
2021-12-01
These findings suggest that machine learning algorithms could accurately predict incident dementia within 2 years in patients receiving care at memory clinics using only 6 variables. 5 key findings →
Design: prospective cohort
Participants: 307
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
66/100
✓ Peer-reviewed
alzhub usefulness score 66 out of 100.
·
JAMA network open
·
2022-08-01
At baseline, there were 436 asymptomatic individuals, 69 patients with prodromal AD, and 127 with AD dementia. 2 key findings →
Design: cohort study
Participants: 632
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
66/100
✓ Peer-reviewed
alzhub usefulness score 66 out of 100.
·
JAMA network open
·
2024-09-03
There were 132 720 unique adults with Down syndrome from 2011 to 2019: 79 578 (53.2%) were male, 17 090 (11.7%) were non-Hispanic Black, 20 777 (15.7%) were Hispanic, 101 120 (68.8%) were non-Hispanic White, and 47 692 (23.3%) had ever had an Alzheimer dementia diagnosis. 3 key findings →
Design: cohort study
Participants: 132
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
66/100
✓ Peer-reviewed
alzhub usefulness score 66 out of 100.
·
JAMA network open
·
2023-11-01
Epidemiological evidence regarding the association between atrial fibrillation (AF) onset age and risk of incident dementia remains unexplored. 4 key findings →
Design: cohort study
Participants: 746
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
66/100
✓ Peer-reviewed
alzhub usefulness score 66 out of 100.
·
JAMA network open
·
2022-08-01
Men, racial and ethnic minority individuals, older adults, and those with language barriers are at increased risk for undertreatment of depression. 5 key findings →
Design: cohort study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
66/100
✓ Peer-reviewed
alzhub usefulness score 66 out of 100.
·
JAMA network open
·
2024-08-01
Among the cohort of 7180 older adults (median age, 74 years [range, 65-102 years]; 4729 women [65.9%]), 1036 were African American or Black (14.4%), 21 were American Indian or Alaska Native (0.3%), 143 were Asian (2.0%), 332 were Hispanic (4.6%), and 5648 were non-Hispanic White (78.7%); the median educational level was 16.0 years (range, 1.0-29.0 years). 5 key findings →
Design: cohort study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
66/100
✓ Peer-reviewed
alzhub usefulness score 66 out of 100.
·
JAMA network open
·
2024-10-01
The sample included 1 626 127 Medicare beneficiaries (mean [SD] age, 80.1 [8.0] years; 922 194 women [56.7%]) who received diagnoses of the 4 conditions in 2016. 5 key findings →
Design: cohort study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor,
and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a
scientist can tell a landmark trial from a conference abstract without having to already know the
difference. Every point comes from one of 20 components, all of them printed on the study itself,
so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we
could not verify current impact factors from a source we control, and an invented one would be
worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science,
Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed
journal. A separate part scores how much the journal's own papers are cited, which tells the
tier-3 journals apart.
Two rules we don't bend. First, we never fill in a
missing value: if a record does not state a sample size or a design, that component scores
zero, and if we simply have no data for a part, such as a citation count, that part is left out and
the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed
article is capped at 16/100 and carries a warning chip — so a conference abstract or
a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not
work — above an early positive finding. Someone deciding whether to buy a supplement is served by
that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is
reproducible: the same file always yields the same numbers.
See the whole rubric drawn out →
— four charts covering all 27,380 studies: how the scores are spread and where the cap
bites, which of the 20 components the library is strong and weak on, which subjects rest on
stronger evidence, and what kinds of study each subject is actually built from.